Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT05736965
- Locations
- 🇨🇳
Jilin University China Japan Union Hospital, Ch'ang-ch'un, China
🇨🇳Changzhou Municipal No.1 People's Hospital, Changzhou, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, China
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Venetoclax After TKI to Target Persisting Stem Cells in CML
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Thomas Ernst, PD Dr. med.
- Target Recruit Count
- 10
- Registration Number
- NCT05701215
- Locations
- 🇩🇪
Uniklinik der RWTH Aachen, Aachen, Germany
🇩🇪Universitätsklinikum Jena, Jena, Germany
Pirtobrutinib and Venetoclax with MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingDrug: PirtobrutinibProcedure: Positron Emission TomographyDrug: VenetoclaxProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Biopsy
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 72
- Registration Number
- NCT05677919
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 18
- Registration Number
- NCT05668026
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)Diffuse Large B-cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)MDS/Myeloproliferative Neoplasm (MPN) Overlap SyndromeRichter's SyndromeT-cell LymphomaChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 274
- Registration Number
- NCT05665530
- Locations
- 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 184
- Registration Number
- NCT05628623
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 38
- Registration Number
- NCT05618366
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presberteryian Hospital, New York, New York, United States
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 132
- Registration Number
- NCT05600894
- Locations
- 🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.